2021
DOI: 10.1097/cad.0000000000001200
|View full text |Cite
|
Sign up to set email alerts
|

Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data

Abstract: We performed a systematic review and meta-analysis to evaluate the role of platinum-based adjuvant chemotherapy (AC) in upper tract urothelial carcinoma. Eligible studies were identified using Pubmed/Medline, Cochrane library, Embase and meeting abstracts. Outcomes of interest included: overall survival (OS), cancer-specific survival (CSS) and disease-free survival (DFS). Platinum-based AC was associated with improved DFS, while the benefit in OS and CSS was not statistically significant compared to observatio… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

0
4
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(4 citation statements)
references
References 45 publications
0
4
0
Order By: Relevance
“…Recent advancements in perioperative systemic therapy strategies in UTUC [7,8] further highlight the importance of a thorough diagnostic workup, which includes choosing the best timing for systemic therapy in light of potential lower kidney function following surgery [9]. Possibly, further understanding of UTUC molecular variants might affect both diagnostic and treatment strategies [10].…”
Section: Introductionmentioning
confidence: 99%
“…Recent advancements in perioperative systemic therapy strategies in UTUC [7,8] further highlight the importance of a thorough diagnostic workup, which includes choosing the best timing for systemic therapy in light of potential lower kidney function following surgery [9]. Possibly, further understanding of UTUC molecular variants might affect both diagnostic and treatment strategies [10].…”
Section: Introductionmentioning
confidence: 99%
“…Recent advancements in perioperative systemic therapy strategies in UTUC [7,8] further highlight the importance of a thorough diagnostic workup, which includes choosing the best timing for systemic therapy in light of potential lower kidney function following surgery [9]. Possibly, further understanding of UTUC molecular variants might affect both diagnostic and treatment strategies [10].…”
Section: Introductionmentioning
confidence: 99%
“…A phase III POUT trial has demonstrated the benefit of platinum-based AC for patients with locally advanced UTUC [ 18 ]. A meta-analysis has reported that platinum-based AC is associated with improved disease-free survival (DFS) for locally advanced UCs [ 19 ]. Alternatively, immune checkpoint inhibitors (ICIs) that had been investigated as an adjuvant treatment of UTUC in the CheckMate-274 trial (nivolumab) may be considered [ 20 ].…”
Section: Introductionmentioning
confidence: 99%